Luye Pharma Group

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Luye Pharma Group sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).

22 total trials none currently recruiting 21 completed early-phase tilt top decile by trial count

Luye Pharma Group: 22 sponsored US clinical trials, none currently recruiting.

Luye Pharma Group sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 21 completed. 1 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 3 trials.

Top-decile sponsor footprint

Luye Pharma Group ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

21 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

22 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Comparative Efficacy, Safety, PK, and Immunogenicity Study

NCT05853354
COMPLETED Phase 1

A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects

NCT07671833
COMPLETED Phase 1

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

NCT05321602
COMPLETED Phase 1

Relative Bioavailability of LY03010 Compared to Listed Drug

NCT04922593
COMPLETED Phase 1

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

NCT04384666
COMPLETED Phase 1

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

NCT04572685
COMPLETED Phase 1

A Relative Bioavailability Food Effect Study of LY03005

NCT03822065
COMPLETED Phase 1

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

NCT03751488
COMPLETED Phase 1

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

NCT03733561
COMPLETED Phase 1

A Study of LY03005 vs Pristiq

NCT03733574
COMPLETED Phase 1

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

NCT03589066
COMPLETED Phase 1

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

NCT03450109
COMPLETED Phase 1

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

NCT03357796
COMPLETED Phase 1

Pilot BA Study of New LY03005 vs Pristiq

NCT02988024
COMPLETED Phase 1

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

NCT02728947
COMPLETED Phase 1

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

NCT02603770
COMPLETED Phase 1

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

NCT02271412
COMPLETED Phase 1

Bioavailability of LY03004 and Risperdal® Consta®

NCT02091388
COMPLETED Phase 1

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02186769
COMPLETED Phase 1

Safety, Tolerability and Pharmacokinetics Study of LY03005

NCT02055300
COMPLETED Phase 1

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

NCT02055274
COMPLETED Phase 1

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02055287

Phase Distribution

PhaseTrial count
Phase 1 21
Phase 3 1

Therapeutic Areas

Schizophrenia 3
Schizoaffective Disorder 2
Schizophrenia Patients 1
Central Nervous System Depressants 1
Tranquilizing Agents 1
Antipsychotic Agents 1
Schizophrenia Spectrum 1
Psychotropic Drugs 1
Lipid Metabolism Disorder 1
Psychotic Disorders 1

How the Luye Pharma Group early-phase archive is shaped

22 indexed studies, none listed as recruiting (0% open); 21 completed (95%).

Phase mix: 1 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Schizophrenia (3 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Luye Pharma Group: archived-pipeline peers nationwide

Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Luye Pharma Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15% Total trials Recruiting share Luye Pharma GroupAlaunos TherapeuticsAlexza PharmaceuticalsCalithera BiosciencesFate Therapeutics10xBio22nd Century Group23andMe3-C Institute for Social Development
Luye Pharma Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Luye Pharma Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 22 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Luye Pharma Group page

22 registered trials is a research-attention snapshot, not an endorsement of Luye Pharma Group or any single study.

  • None of Luye Pharma Group's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Schizophrenia is the condition Luye Pharma Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Luye Pharma Group pipeline card: 22 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.